Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1980;71(2):615–622. doi: 10.1111/j.1476-5381.1980.tb10981.x

Evaluation of antagonism of aconitine-induced dysrhythmias in mice as a method of detecting and assessing antidysrhythmic activity.

E Winslow
PMCID: PMC2044441  PMID: 7470765

Abstract

1 Antagonism of aconitine-induced dysrhythmias in mice as a method of detecting and assessing antidysrhythmia activity was evaluated. 2 Aconitine-induced dysrhythmias in mice appear to be selectively sensitive to antidysrhythmia agents (administered intraperitoneally) which reduce the inward sodium current in cardiac cells. 3 Antidysrhythmic agents whose mechanism of action is thought to depend on beta-adrenoceptor blockade, prolongation of cardiac monophasic action potentials or calcium antagonism are ineffective in delaying the onset of aconitine-induced dysrhythmias in mice. The inactive drugs were practolol, sotalol, bretylium, amiodarone and verapamil. 4 Comparisons of anti-dysrhythmic activities of test drugs should be based on more than one ED value and should take account of efficacy as well as potency. 5 The mouse aconitine test is a useful and rapid method of evaluating oral antidysrhythmic activity in terms of potency, efficacy and duration of action. 6 With respect to potency, efficacy, oral activity, duration of action and safety, 3 alpha-amino-5 alpha-androstan-2 beta-ol-17-one hydrochloride (Org 6001) offered the most satisfactory overall profile of the active drugs tested (Org 6001, aprindine, quinidine, disopyramide, lignocaine, mexiletine, procainamide and propranolol).

Full text

PDF
615

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cabasson J., Mellet J. M., Guimond C., Bachy C., Sassine A., Puech P. L'etude des potentiels d'action monophasiques du myocarde par voie endocavitaire et ses applications. Ann Cardiol Angeiol (Paris) 1975 Nov-Dec;24(6):483–490. [PubMed] [Google Scholar]
  2. Coltart D. J., Meldrum S. J. The effect of racemic propranolol, dextro-propranolol and racemic practolol on the human and canine cardiac transmembrane action potential (beta blockade and the cardiac action potential). Arch Int Pharmacodyn Ther. 1971 Jul;192(1):188–197. [PubMed] [Google Scholar]
  3. Dadkar N. K., Bhattacharya B. K. A rapid screening procedure for antiarrhythmic activity in the mouse. Arch Int Pharmacodyn Ther. 1974 Dec;212(2):297–301. [PubMed] [Google Scholar]
  4. Hulting J., Jansson B. Antiarrhythmic and electrocardiographic effects of single oral doses of disopyramide. Eur J Clin Pharmacol. 1977 Jan 3;11(2):91–99. doi: 10.1007/BF00562898. [DOI] [PubMed] [Google Scholar]
  5. Nwangwu P. U., Holcslaw T. L., Stohs S. J. A rapid in vivo technique for preliminary screening of antiarrhythmic agents in mice. Arch Int Pharmacodyn Ther. 1977 Oct;229(2):219–226. [PubMed] [Google Scholar]
  6. Prescott L. F., Pottage A., Clements J. A. Absorption, distribution and elimination of mexiletine. Postgrad Med J. 1977;53 (Suppl 1):50–55. [PubMed] [Google Scholar]
  7. SEKIYA A., VAUGHANWILLIAMS E. M. A COMPARISON OF THE ANTIFIBRILLATORY ACTIONS AND EFFECTS ON INTRACELLULAR CARDIAC POTENTIALS OF PRONETHALOL, DISOPYRAMIDE AND QUINIDINE. Br J Pharmacol Chemother. 1963 Dec;21:473–481. doi: 10.1111/j.1476-5381.1963.tb02015.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Salako L. A., Williams V., Wittig J. H. Investigations to characterize a new anti-arrhythmic drug, ORG 6001 including a simple test for calcium antagonism. Br J Pharmacol. 1976 Jun;57(2):251–262. doi: 10.1111/j.1476-5381.1976.tb07475.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Singh B. N. A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc Res. 1972 Mar;6(2):109–119. doi: 10.1093/cvr/6.2.109. [DOI] [PubMed] [Google Scholar]
  10. Singh B. N., Vaughan Williams E. M. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970 Aug;39(4):657–667. doi: 10.1111/j.1476-5381.1970.tb09891.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Steinberg M. I., Greenspan K. Intracellular electrophysiological alterations in canine cardiac conducting tissue induced by aprindine and lignocaine. Cardiovasc Res. 1976 Mar;10(2):236–244. doi: 10.1093/cvr/10.2.236. [DOI] [PubMed] [Google Scholar]
  12. Vargaftig B. B., Sugrue M. F., Buckett W. R., van Riezen H. ORG 6001 (3alpha-amino-5alpha-androstan-2beta-ol-17-one hydrochloride), a steroidal anti-arrhythmic agent. J Pharm Pharmacol. 1975 Sep;27(9):697–699. doi: 10.1111/j.2042-7158.1975.tb09535.x. [DOI] [PubMed] [Google Scholar]
  13. Vargaftig B., Coignet J. L. A critical evaluation of three methods for the study of adrenergic beta-blocking and anti-arrhythmic agents. Eur J Pharmacol. 1969 Apr;6(1):49–55. doi: 10.1016/0014-2999(69)90064-8. [DOI] [PubMed] [Google Scholar]
  14. Wit A. L., Steiner C., Damato A. N. Electrophysiologic effects of bretylium tosylate on single fibers of the canine specialized conducting system and ventricle. J Pharmacol Exp Ther. 1970 Jun;173(2):344–356. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES